ePrints

Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation

Lookup NU author(s): Professor Stephen Proctor, Dr Penelope Taylor

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

A multicentre, randomised vehicle-controlled single-blind dose ranging trial of intravenous recombinant granulocyte colony-stimulating factor (rhuG-CSF) administration after BMT has been performed in 121 patients with non-myeloid malignancies. All the doses of rhuG-CSF used (2-20 mug/kg/day) resulted in significant acceleration of neutrophil recovery, and a dose-response effect was apparent (p < 0.05). At the 20 mug/kg/day dose of rhuG-CSF the median time taken to achieve a neutrophil count of >0.5 X 10(9)/l was reduced from 19 to 13 days (p < 0.001) and the time to achieve a neutrophil count >1.0 x 10(9)/l on the first of 3 consecutive days, from 26 to 14 days (p < 0.001). There was a trend to less antibiotic use in the rhuG-CSF recipients and the median time in hospital was markedly reduced by 11-15 days (p < 0.01). There was no toxicity in this study attributable to rhuG-CSF.

Publication metadata

Author(s): Linch, D. C., Scarffe, H., Proctor, S. J., Chopra, R., Taylor, P. R. A., Morgenstern, G., Cunningham, D., Burnett, A. K., Cawley, J. C., Franklin, I. M., Bell, A. J., Lister, T. A., Marcus, R. E., Newland, A. C., Parker, A. C., Yver, A.

Publication type: Article

Publication status: Published

Journal: Bone Marrow Transplantation

Year: 1993

Volume: 11

Issue: 4

Pages: 307-311

Print publication date: 01/04/1993

ISSN (print): 0268-3369

ISSN (electronic): 1476-5365

PubMed id: 7683552

Share